Table 3 Distribution of study outcomes in COPD/CB patients during one year prior to baseline
Outcome variable | Categories | Female N = 47,487 (53.6%) | Male N = 41,061 (46.4%) | P-value | Total N = 88,548 (100%) |
|---|---|---|---|---|---|
All cause hospitalizations | 0.97 ± 1.78 | 1.08 ± 1.98 | <0.001 | 1.02 ± 1.88 | |
0 | 27,540 (58.0) | 23,172 (56.4) | 50,712 (57.3) | ||
1-2 | 14,105 (29.7) | 12,145 (29.6) | 26,250 (29.6) | ||
3-5 | 4500 (9.5) | 4331 (10.5) | 8831 (10.0) | ||
>5 | 1342 (2.8) | 1413 (3.4) | 2755 (3.1) | ||
All cause secondary care out-patient visits | 2.82 ± 5.28 | 3.01 ± 7.45 | <0.001 | 2.91 ± 6.38 | |
0 | 13,600 (28.6) | 11,812 (28.8) | 25,412 (28.7) | ||
1-2 | 16,333 (34.4) | 13,941 (34.0) | 30,274 (34.2) | ||
3-5 | 10,674 (22.5) | 9303 (22.7) | 19,977 (22.6) | ||
>5 | 6880 (14.5) | 6005 (14.6) | 12,885 (14.6) | ||
Respiratory hospitalizations | 0.27 ± 0.89 | 0.27 ± 0.87 | 0.273 | 0.27 ± 0.88 | |
0 | 40,224 (84.7) | 34,857 (84.9) | 75,081 (84.8) | ||
1-2 | 6070 (12.8) | 5167 (12.6) | 11,237 (12.7) | ||
3-5 | 953 (2.0) | 865 (2.1) | 1818 (2.1) | ||
>5 | 240 (0.5) | 172 (0.4) | 412(0.5) | ||
Systemic corticosteroid purchases | 1.28 ± 4.19 | 0.99 ± 3.34 | <0.001 | 1.15 ± 3.82 | |
0 | 32,141 (67.7) | 29,932 (72.9) | 62,073 (70.1) | ||
1-2 | 8935 (18.8) | 6530 (15.9) | 15,465 (17.5) | ||
3-5 | 4112 (8.7) | 3024 (7.4) | 7136 (8.1) | ||
>5 | 2299 (4.8) | 1575 (3.8) | 3874 (4.4) | ||
Systemic antibiotic purchases | 1.60 ± 2.90 | 1.24 ± 2.34 | <0.001 | 1.44 ± 2.66 | |
0 | 20,827 (43.9) | 20,833 (50.7) | 41,660 (47.0) | ||
1-2 | 17,029 (35.9) | 13,867 (33.8) | 30,896 (34.9) | ||
3-5 | 6814 (14.3) | 4716 (11.5) | 11,530 (13.0) | ||
>5 | 2817 (5.9) | 1645 (4.0) | 4462 (5.0) |